Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €41.13 EUR
Change Today +0.69 / 1.70%
Volume 0.0
ILR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:35 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (ILR) Snapshot

Open
€40.27
Previous Close
€40.44
Day High
€41.40
Day Low
€40.17
52 Week High
04/13/15 - €49.00
52 Week Low
08/4/14 - €16.58
Market Cap
2.9B
Average Volume 10 Days
13.0
EPS TTM
--
Shares Outstanding
71.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPAX LABORATORIES INC (ILR)

impax laboratories inc (ILR) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (ILR) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

1,061 Employees
Last Reported Date: 02/26/15
Founded in 1993

impax laboratories inc (ILR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $552.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $446.2K
President of Impax Pharmaceuticals
Total Annual Compensation: $515.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $484.2K
Senior Vice President of Technical Operations
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.

impax laboratories inc (ILR) Key Developments

Impax Laboratories Mulls Acquisitions

Impax Laboratories Inc. (NasdaqGS:IPXL) is seeking acquisitions. Impax Laboratories priced $500 million principal amount of 2% convertible senior notes due 2022 in a private offering to qualified institutional buyers. If the initial purchasers exercise their option to purchase additional notes, Impax Laboratories intends to enter into additional convertible note hedge and warrant transactions and use a portion of the net proceeds from the sale of the additional notes to pay the cost of the additional convertible note hedge transaction. Impax Laboratories may also use a portion of the net proceeds to acquire new businesses through one or more acquisitions or other strategic transactions; however, the Company has no current commitments or obligations with respect to any acquisitions or other strategic transactions.

Impax Laboratories Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-11-2015 09:20 AM

Impax Laboratories Inc. Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-11-2015 09:20 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Bryan M. Reasons, Chief Financial Officer and Senior Vice President of Finance, Fred Wilkinson, President and CEO.

Impax Laboratories, Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015

Impax Laboratories Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company has reported that net loss for the first quarter ended March 31, 2015 was $6.33 million, or $0.09 loss per share, compared to a net income of $6.42 million, or $0.09 per share, for the same quarter ended March 31, 2014. Total revenues for the first quarter ended March 31, 2015 were $143.1 million, compared to $118.72 million for the same quarter ended March 31, 2014. Loss from operations for the first quarter ended March 31, 2015 was $6.85 million, compared to an income from operations of $8.23 million for the same quarter ended March 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILR:GR €41.13 EUR +0.69

ILR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Emergent BioSolutions Inc $32.95 USD +0.87
Inter Parfums Inc $33.93 USD -0.10
Jubilant Life Sciences Ltd 168.80 INR +1.80
Lifetime Brands Inc $14.77 USD +0.05
View Industry Companies
 

Industry Analysis

ILR

Industry Average

Valuation ILR Industry Range
Price/Earnings 14.0x
Price/Sales 1.0x
Price/Book 0.7x
Price/Cash Flow 11.8x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit www.impaxlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.